ID
13683
Description
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT01465230
Link
https://clinicaltrials.gov/show/NCT01465230
Keywords
Versions (1)
- 2/28/16 2/28/16 -
Uploaded on
February 28, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Chronic Lymphocytic Leukemia NCT01465230
Eligibility Chronic Lymphocytic Leukemia NCT01465230
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
comorbidity affecting treatment
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0009488
- UMLS CUI [1,2]
- C0392760
- UMLS CUI [1,3]
- C0087111
Description
tumor lysis syndrome
Data type
boolean
Alias
- UMLS CUI [1]
- C0041364
Description
treatment lenalidomide
Data type
boolean
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C1144149
Similar models
Eligibility Chronic Lymphocytic Leukemia NCT01465230
- StudyEvent: Eligibility
C0857127 (UMLS CUI [1,2])
C0525079 (UMLS CUI [2])
C0392760 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C1144149 (UMLS CUI [1,2])